OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Treating Mantle Cell Lymphoma: Role of BTK Inhibition

home / insights / mcl-btk-inhibition
Advertisement
Understanding the Heterogeneity of Mantle Cell Lymphoma

EP. 1: Understanding the Heterogeneity of Mantle Cell Lymphoma

January 18th 2019
Mantle Cell Lymphoma: Impact of Genetic Variants

EP. 2: Mantle Cell Lymphoma: Impact of Genetic Variants

January 18th 2019
Distinguishing MCL From Other Lymphomas

EP. 3: Distinguishing MCL From Other Lymphomas

January 18th 2019
Mantle Cell Lymphoma: An Overview of Therapy

EP. 4: Mantle Cell Lymphoma: An Overview of Therapy

January 18th 2019
Optimizing Therapeutic Approaches to MCL

EP. 5: Optimizing Therapeutic Approaches to MCL

January 18th 2019
Selecting Therapy for Relapsed/Refractory MCL

EP. 6: Selecting Therapy for Relapsed/Refractory MCL

January 18th 2019
Advertisement
Ibrutinib in MCL: Changing the Treatment Landscape

EP. 7: Ibrutinib in MCL: Changing the Treatment Landscape

January 18th 2019
MCL: Long-Term Safety/Efficacy Data With Ibrutinib

EP. 8: MCL: Long-Term Safety/Efficacy Data With Ibrutinib

January 18th 2019
Managing Adverse Events of Ibrutinib in Patients With MCL

EP. 9: Managing Adverse Events of Ibrutinib in Patients With MCL

January 18th 2019
Considering Off-Label Use of Ibrutinib in MCL

EP. 10: Considering Off-Label Use of Ibrutinib in MCL

January 18th 2019
MCL: Novel BTK Inhibitor Combination Strategies

EP. 11: MCL: Novel BTK Inhibitor Combination Strategies

January 18th 2019
Non-BTKi Agents' Role in Mantle Cell Lymphoma

EP. 12: Non-BTKi Agents' Role in Mantle Cell Lymphoma

January 18th 2019
Advertisement
Advice for Future Management of Mantle Cell Lymphoma

EP. 13: Advice for Future Management of Mantle Cell Lymphoma

January 18th 2019
Personal Insight Into Ibrutinib Use in Mantle Cell Lymphoma

EP. 14: Personal Insight Into Ibrutinib Use in Mantle Cell Lymphoma

January 18th 2019
MCL: Differences in Trial Design Between BTK Inhibitors

EP. 15: MCL: Differences in Trial Design Between BTK Inhibitors

January 18th 2019
Identifying Unmet Needs in Relapsed/Refractory MCL

EP. 16: Identifying Unmet Needs in Relapsed/Refractory MCL

January 18th 2019
Differentiating BTK Inhibitor Mechanisms of Action in MCL

EP. 17: Differentiating BTK Inhibitor Mechanisms of Action in MCL

January 18th 2019

Latest Conference Coverage

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact